Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S7ZQ
|
||||
| Former ID |
DNC009854
|
||||
| Drug Name |
4'-Methoxy-5,3'-dipropyl-biphenyl-2ol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H24O2
|
||||
| Canonical SMILES |
CCCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)OC)CCC
|
||||
| InChI |
1S/C19H24O2/c1-4-6-14-8-10-18(20)17(12-14)15-9-11-19(21-3)16(13-15)7-5-2/h8-13,20H,4-7H2,1-3H3
|
||||
| InChIKey |
HFEJJSAHPYKAPW-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | mRNA of human 5-lipoxygenase | Target Info | Inhibitor | [1] | |
| Prostaglandin G/H synthase 1 | Target Info | Inhibitor | [1] | ||
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Resolvin D biosynthesis | |||||
| Leukotriene biosynthesis | |||||
| Lipoxin biosynthesis | |||||
| Aspirin triggered resolvin D biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesisPWY66-374:C20 prostanoid biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Toxoplasmosishsa00590:Arachidonic acid metabolism | |||||
| Platelet activation | |||||
| NetPath Pathway | IL4 Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | ||||
| PathWhiz Pathway | Arachidonic Acid MetabolismPW000044:Arachidonic Acid Metabolism | ||||
| WikiPathways | Arachidonic acid metabolism | ||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient NetworkWP98:Prostaglandin Synthesis and Regulation | |||||
| Phase 1 - Functionalization of compounds | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. Epub 2009 May 18.Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxygenase-mediated LTB4-formation. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.